<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recently, <z:mp ids='MP_0001845'>inflammation</z:mp> has received considerable attention in the pathogenesis of both type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The interleukin-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (IL-1ra) is a major modulator of the interleukin-1 pro-inflammatory pathway </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the relationship between a variable number tandem repeat (VNTR) polymorphism in intron 2 of the IL-1ra gene (IL1RN) and <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) in patients with and without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, following 787 consecutive patients admitted for suspected CAD </plain></SENT>
<SENT sid="3" pm="."><plain>According to the current criteria of the American <z:mp ids='MP_0002055'>Diabetes</z:mp> Association, 250 patients had type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In this group of patients, allele 2 carriers (n = 108) had an increased prevalence of CAD compared with noncarriers (85.2 vs. 73.2%), a difference that remained significant in a multivariate logistic regression model (odds ratio 2.2, 95% CI 1.1-4.3, P = 0.02) </plain></SENT>
<SENT sid="5" pm="."><plain>No association of CAD with allele 2 carrier status was present among nondiabetic patients (n = 537) </plain></SENT>
<SENT sid="6" pm="."><plain>Enzyme-linked immunosorbent assays showed decreased baseline plasma levels of IL-1ra in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, which may in part explain the role of the IL1RN VNTR in these patients </plain></SENT>
</text></document>